These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

567 related items for PubMed ID: 23947935

  • 1. Clinical efficacy of dofetilide for the treatment of atrial tachyarrhythmias in adults with congenital heart disease.
    Banchs JE, Baquero GA, Nickolaus MJ, Wolbrette DL, Kelleman JJ, Samii S, Grando-Ting J, Penny-Peterson E, Davidson WR, Young SK, Naccarelli GV, Gonzalez MD.
    Congenit Heart Dis; 2014; 9(3):221-7. PubMed ID: 23947935
    [Abstract] [Full Text] [Related]

  • 2. Dofetilide: a review of its use in atrial fibrillation and atrial flutter.
    McClellan KJ, Markham A.
    Drugs; 1999 Dec; 58(6):1043-59. PubMed ID: 10651390
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group.
    Nørgaard BL, Wachtell K, Christensen PD, Madsen B, Johansen JB, Christiansen EH, Graff O, Simonsen EH.
    Am Heart J; 1999 Jun; 137(6):1062-9. PubMed ID: 10347332
    [Abstract] [Full Text] [Related]

  • 4. A Quarter of a Century Later: What is Dofetilide's Clinical Role Today?
    Wolbrette DL, Hussain S, Maraj I, Naccarelli GV.
    J Cardiovasc Pharmacol Ther; 2019 Jan; 24(1):3-10. PubMed ID: 29940780
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of dofetilide in patients with atrial fibrillation and atrial flutter.
    Banchs JE, Wolbrette DL, Samii SM, Penny-Peterson ED, Patel PP, Young SK, Gonzalez MD, Naccarelli GV.
    J Interv Card Electrophysiol; 2008 Nov; 23(2):111-5. PubMed ID: 18688699
    [Abstract] [Full Text] [Related]

  • 6. Dofetilide: a new class III antiarrhythmic agent.
    Roukoz H, Saliba W.
    Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):9-19. PubMed ID: 17187453
    [Abstract] [Full Text] [Related]

  • 7. Use of dofetilide in adult patients with atrial arrhythmias and congenital heart disease: A PACES collaborative study.
    El-Assaad I, Al-Kindi SG, Abraham J, Sanatani S, Bradley DJ, Halsey C, Law IH, Balaji S, Shetty I, Aziz PF.
    Heart Rhythm; 2016 Oct; 13(10):2034-9. PubMed ID: 27435587
    [Abstract] [Full Text] [Related]

  • 8. Role of dofetilide in patients with atrial fibrillation. Insights from the Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) study.
    Singh SN.
    Card Electrophysiol Rev; 2003 Sep; 7(3):225-8. PubMed ID: 14739718
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study.
    Singh S, Zoble RG, Yellen L, Brodsky MA, Feld GK, Berk M, Billing CB.
    Circulation; 2000 Nov 07; 102(19):2385-90. PubMed ID: 11067793
    [Abstract] [Full Text] [Related]

  • 10. Acute conversion of persistent atrial fibrillation during dofetilide loading does not predict long-term atrial fibrillation-free survival.
    Khurshid S, Akerman S, Man JP, Supple G, Dixit S, Epstein AE, Marchlinski FE, Frankel DS.
    J Interv Card Electrophysiol; 2015 Mar 07; 42(2):117-24. PubMed ID: 25620152
    [Abstract] [Full Text] [Related]

  • 11. Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function.
    Mykytsey A, Bauman JL, Razminia M, Zheutlin T, Wang T, Saleem M, Leal S, Kehoe RF.
    J Cardiovasc Pharmacol Ther; 2007 Mar 07; 12(1):36-43. PubMed ID: 17495256
    [Abstract] [Full Text] [Related]

  • 12. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group.
    Torp-Pedersen C, Møller M, Bloch-Thomsen PE, Køber L, Sandøe E, Egstrup K, Agner E, Carlsen J, Videbaek J, Marchant B, Camm AJ.
    N Engl J Med; 1999 Sep 16; 341(12):857-65. PubMed ID: 10486417
    [Abstract] [Full Text] [Related]

  • 13. Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicentre, randomized, double-blind, placebo-controlled study.
    Bianconi L, Castro A, Dinelli M, Alboni P, Pappalardo A, Richiardi E, Santini M.
    Eur Heart J; 2000 Aug 16; 21(15):1265-73. PubMed ID: 10924317
    [Abstract] [Full Text] [Related]

  • 14. Acute conversion of persistent atrial fibrillation during dofetilide initiation.
    Cotiga D, Arshad A, Aziz E, Joshi S, Koneru JN, Steinberg JS.
    Pacing Clin Electrophysiol; 2007 Dec 16; 30(12):1527-30. PubMed ID: 18070309
    [Abstract] [Full Text] [Related]

  • 15. Intravenous magnesium sulfate enhances the ability of dofetilide to successfully cardiovert atrial fibrillation or flutter: results of the Dofetilide and Intravenous Magnesium Evaluation.
    Coleman CI, Sood N, Chawla D, Talati R, Ghatak A, Kluger J, Dofetilide and Intravenous Magnesium Evaluation (DIME) Investigators.
    Europace; 2009 Jul 16; 11(7):892-5. PubMed ID: 19351630
    [Abstract] [Full Text] [Related]

  • 16. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
    Naccarelli GV, Wolbrette DL, Khan M, Bhatta L, Hynes J, Samii S, Luck J.
    Am J Cardiol; 2003 Mar 20; 91(6A):15D-26D. PubMed ID: 12670638
    [Abstract] [Full Text] [Related]

  • 17. Five-year follow-up after catheter ablation of persistent atrial fibrillation using the stepwise approach and prognostic factors for success.
    Schreiber D, Rostock T, Fröhlich M, Sultan A, Servatius H, Hoffmann BA, Lüker J, Berner I, Schäffer B, Wegscheider K, Lezius S, Willems S, Steven D.
    Circ Arrhythm Electrophysiol; 2015 Apr 20; 8(2):308-17. PubMed ID: 25744570
    [Abstract] [Full Text] [Related]

  • 18. Dofetilide: a new pure class III antiarrhythmic agent.
    Falk RH, Decara JM.
    Am Heart J; 2000 Nov 20; 140(5):697-706. PubMed ID: 11054613
    [Abstract] [Full Text] [Related]

  • 19. Celivarone for maintenance of sinus rhythm and conversion of atrial fibrillation/flutter.
    Khitri AR, Aliot EM, Capucci A, Connolly SJ, Crijns H, Hohnloser SH, Kulakowski P, Roy D, Radzik D, Kowey PR.
    J Cardiovasc Electrophysiol; 2012 May 20; 23(5):462-72. PubMed ID: 22171925
    [Abstract] [Full Text] [Related]

  • 20. Magnitude of increase in QTc interval after initiation of dofetilide in patients with persistent atrial fibrillation is associated with increased rates of pharmacological cardioversion and long-term freedom from recurrent atrial fibrillation.
    Huang HD, Waks JW, Steinhaus DA, Zimetbaum P.
    Heart Rhythm; 2016 Jul 20; 13(7):1410-7. PubMed ID: 26921760
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.